Acadia Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Acadia Pharmaceuticals (San Diego, CA): 3 reconciled FDA prescription therapies (71.9% 2025 to 2030 cliff risk), $932.0M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | San Diego, CA |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 71.9% |
| Primary Portfolio LOE Date | 2037-01-01 |
| 2024 CMS Total Public Spend | $932.0M |
| 2024 Medicare Part D Spend | $697.4M |
| 2024 Medicaid Spend | $234.6M |
| California HCAI SB 17 Filings | 3 WAC filings (max 37.3% 2-yr change) |